Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam

References

• HIV/AIDS. World Health Organization. Fact sheet [Internet] http://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 1127, 2018.
   Google Scholar
• Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115–123. doi:10.3851/IMP243723052978
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Nurutdinova D, Grubb JR, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(3):259–264. doi:10.1089/aid.2011.002221877906
   PubMed Web of Science ®Google Scholar
• Ruperez M, Pou C, Maculuve S, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639–2647. doi:10.1093/jac/dkv14326084302
   PubMed Web of Science ®Google Scholar
• Dean J, Ta Thi TH, Dunford L, et al. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses. 2011;27(7):797–801. doi:10.1089/aid.2011.001321366425
   PubMed Web of Science ®Google Scholar
• Bontell I, Cuong Do D, Agneskog E, Diwan V, Larsson M, Sonnerborg A. Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. Infect Genet Evol. 2012;12(2):448–452. doi:10.1016/j.meegid.2011.04.03421620998
   PubMed Web of Science ®Google Scholar
• Tran VT, Ishizaki A, Nguyen CH, et al. No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in Northern Vietnam. AIDS Res Hum Retroviruses. 2012;28(10):1349–1351. doi:10.1089/aid.2012.000622264087
   PubMed Web of Science ®Google Scholar
• Tanuma J, Quang VM, Hachiya A, et al. Low prevalence of transmitted drug resistance of HIV-1 during 2008–2012 antiretroviral therapy scaling up in Southern Vietnam. J Acquir Immune Defic Syndr. 2014;66(4):358–364. doi:10.1097/QAI.000000000000019624815852
   PubMed Web of Science ®Google Scholar
• Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–371. doi:10.1016/S1473-3099(11)70032-921354861
   PubMed Web of Science ®Google Scholar
• The National Guidelines for Diagnosis and Treatment of HIV/AIDS. Vietnamese Ministry of Health. Hanoi: Ministry of Health; 2009.
   Google Scholar
• The National Guidelines for Diagnosis and Treatment of HIV/AIDS. Vietnamese Ministry of Health. Hanoi: Ministry of Health; 2005.
   Google Scholar
• Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. World Health Organization. Geneva: Author; 2006.
   Google Scholar
• Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system. J Clin Microbiol. 2003;41(4):1594–1599.12682150
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Duc NB, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther. 2008;13:115.
   Web of Science ®Google Scholar
• Ayouba A, Lien TT, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d’Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses. 2009;25(11):1193–1196. doi:10.1089/aid.2009.014219886834
   PubMed Web of Science ®Google Scholar
• Duc NB, Hien BT, Wagar N, et al. Surveillance of transmitted HIV drug resistance using matched plasma and dried blood spot specimens from voluntary counseling and testing sites in Ho Chi Minh City, Vietnam, 2007–2008. Clin Infect Dis. 2012;54(suppl_4):S343–S347. doi:10.1093/cid/cir104922544201
   PubMed Web of Science ®Google Scholar
• UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 2010;50(9):1275–1285. doi:10.1086/65168420353366
   PubMed Web of Science ®Google Scholar
• Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13 Suppl A:S271–S278.10885784
   PubMed Web of Science ®Google Scholar
• Aghokeng AF, Monleau M, Eymard-Duvernay S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis. 2014;58(1):99–109. doi:10.1093/cid/cit62724076968
   PubMed Web of Science ®Google Scholar
• Pham QD, Do NT, Le YN, et al. Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10. J Antimicrob Chemother. 2015;70(3):941–947. doi:10.1093/jac/dku47325433009
   PubMed Web of Science ®Google Scholar
• Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother. 2000;44(8):2109–2117.10898683
   PubMed Web of Science ®Google Scholar
• Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS. 2000;14(2):F9–15.10708277
   PubMed Web of Science ®Google Scholar
• Yahi N, Fantini J, Henry M, Tourres C, Tamalet C. Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy. J Biomed Sci. 2005;12(5):701–710. doi:10.1007/s11373-005-9011-416200350
   PubMed Web of Science ®Google Scholar
• Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4):156–164.22156218
   PubMedGoogle Scholar
• Winand R, Theys K, Eusebio M, et al. Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals. AIDS. 2015;29(15):2045–2052. doi:10.1097/QAD.000000000000081126355575
   PubMed Web of Science ®Google Scholar
• El Annaz H, Recordon-Pinson P, Tagajdid R, et al. Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. AIDS Res Hum Retroviruses. 2012;28(8):944–948. doi:10.1089/AID.2011.027821919803
   PubMed Web of Science ®Google Scholar
• Miller V, Stark T, Loeliger AE, Lange JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 2002;3(2):135–145.12010361
   PubMedGoogle Scholar
• Liaw Y-F, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531. doi:10.1056/NEJMoa03336415470215
   PubMed Web of Science ®Google Scholar
• Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012;11(5):311–320. doi:10.1177/154510971245393922828983
   PubMedGoogle Scholar
• Dunford L, Carr MJ, Dean J, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One. 2012;7(6):e39027. doi:10.1371/journal.pone.003902722720022
   PubMed Web of Science ®Google Scholar
• Geretti AM. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev. 2006;8(4):210–220.17219736
   PubMed Web of Science ®Google Scholar
• Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, Vandamme AM. Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. J Gen Virol. 2010;91(Pt 8):1898–1908. doi:10.1099/vir.0.022657-020410311
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012;26(11):1345–1354. doi:10.1097/QAD.0b013e328353b06622441252
   PubMed Web of Science ®Google Scholar
• Thao VP, Quang VM, Day JN, et al. High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother. 2016;71(3):762–774. doi:10.1093/jac/dkv38526661398
   PubMed Web of Science ®Google Scholar